Sight Sciences receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Sight Sciences Inc (SGHT)
The Sight Sciences share price today is 10.83, view NASDAQ SGHT stock exchange data. Track the latest Sight Sciences share price with real-time updates on SGHT stock performance including market cap, day range, 52-week range and dividend yield. Access SGHT charts, earnings dates and analyst estimates to support your investment decisions.
NASDAQ
Currency in USD
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
10.75
11.13
52 wk Range
3.38
11.60
SGHT is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
10.7511.13
52 wk Range
3.3811.60
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
SGHT Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Price Target
12.25
Upside
+13.11%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Impressive gross profit margins
Sight Sciences receives Investment Bank Analyst Rating Update- Investing.com
Pro
Form 144 Sight Sciences For: 6 November- Investing.com
- Sight Sciences receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Form 144 Sight Sciences For: 6 November
- Investing.com
Sight Sciences receives Investment Bank Analyst Rating Update- Investing.com
Pro- Sight Sciences receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Sell
Moving Averages
Neutral
Analyst Ratings
6 Buy
2 Hold
0 Sell
Ratings:
8 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 12.25
(+13.11% Upside)
Sight Sciences Inc Earnings Call Summary for Q2/2026
- Q2 revenue rose 20% YoY to $23.4M, fastest growth since 2023; net loss narrowed to $4.4M from $11.9M; shares fell 5.59% after hours.
- Gross margin expanded to 91% from 85%, aided by pricing gains and tariff refunds; interventional dry eye revenue nearly doubled to $2.7M.
- Full-year 2026 revenue guidance raised to $88M-$92M from $83M-$89M; Q3 growth expected in mid-to-high teens year-over-year.
- Operating expenses fell 11% to $25.3M; cash used in Q2 dropped 81% to $1.4M, signaling progress toward cash flow breakeven.
- OMNI Ultra glaucoma device not included in 2026 guidance; broader launch planned for Q4 following AAO conference.
Last Updated: 06-08-2026, 03:10 am
Read Full TranscriptEarnings
Latest Release
04-11-2026
EPS / Forecast
-0.64 / -0.16
Revenue / Forecast
24.92M / 23.55M
Compare SGHT to Peers and Sector
Metrics to compare | SGHT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipSGHTPeersSector | |
|---|---|---|---|---|
P/E Ratio | −21.2x | −2.3x | −0.2x | |
PEG Ratio | −0.52 | −0.16 | 0.00 | |
Price/Book | 12.2x | 2.5x | 2.6x | |
Price / LTM Sales | 6.8x | 3.2x | 2.8x | |
Upside (Analyst Target) | 13.1% | 131.3% | 63.4% | |
Fair Value Upside | Unlock | 20.8% | 9.5% | Unlock |
Sight Sciences, Inc., an ophthalmic medical device company, focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of eye prevalent diseases in the United States. The company operates in two segments, Surgical Glaucoma and Dry Eye. It offers OMNI, a surgical system family of products, such as OMNI Ergo for the catheterization and transluminal viscodilation of Schlemm’s canal and cutting of the trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma; and OMNI EDGE, an implant-free and minimally invasive glaucoma surgery technology. The company also provides SION, a bladeless and manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork; and TearCare system, a proprietary, interventional, dry eye device designed to melt and facilitate the comprehensive removal of meibomian gland obstructions and restore gland functionality and healthy oil production for adult patients with evaporative dry eye disease due to meibomian gland disease when used in conjunction with manual expression of the meibomian glands for ophthalmologists and optometrists. It serves hospitals, medical centers, and eyecare professionals through sales representatives and distributors. The company was incorporated in 2010 and is headquartered in Menlo Park, California.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Sight Sciences (SGHT) Share Price Today?
The Sight Sciences share price today is 10.83.
What is the current Sight Sciences (SGHT) share price and day range?
As of 13-11-2026, the Sight Sciences share price is 10.83, with a previous close of 10.99. The share price has ranged from 10.75 to 11.13 today, while the 52-week range spans from 3.38 to 11.60.
What Is the Sight Sciences Market Cap?
As of today, Sight Sciences market cap is 600.25M.
What Is the Sight Sciences (SGHT) Share Price Target?
The average 12-month share price target for Sight Sciences is 12.25, with a high estimate of 14 and a low estimate of 10. 6 analysts recommend buying, while 0 suggest selling, with an overall rating of Buy and +13.11% Upside potential.
What Is Sight Sciences's Earnings Per Share (TTM)?
The Sight Sciences EPS (TTM) is -0.52.
When Is the Next Sight Sciences Earnings Date?
Sight Sciences will release its next earnings report on 10-03-2027.
From a Technical Analysis Perspective, Is SGHT a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
What Stock Exchange Does Sight Sciences Trade On?
Sight Sciences is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Sight Sciences?
The stock symbol for Sight Sciences is "SGHT."
How Many Times Has Sight Sciences Stock Split?
Sight Sciences has split 0 times.
How Many Employees Does Sight Sciences Have?
Sight Sciences has 186 employees.
What Is the SGHT After Hours Price?
SGHT's last after hours stock price is 10.90, the stock has changed by 0.07, or 0.65%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.